NCT06837155

A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Taisho Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 39 Years
• Healthy volunteers: Accepted

Summary

A clinical study to evaluate the effects on QT/QTc interval of TS-172 in healthy adults subjects

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	TS-172 20 mg	oral administration of TS-172 20 mg
DRUG	TS-172 90 mg	oral administration of TS-172 90 mg
DRUG	Moxifloxacin	oral administration of moxifloxacin 400 mg
DRUG	Placebo	oral administration of placebo

Timeline

• Start date: 2025-03-03
• Primary completion: 2025-05-20
• Completion: 2025-05-26
• First posted: 2025-02-20
• Last updated: 2025-06-06

Locations

1 site across 1 country: Japan